XORTX Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

XORTX Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-50.6%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-50.6%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

Aug 23

XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

Apr 01

We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

Dec 16

Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

Sep 01

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: XRTX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: XRTX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

XORTX Therapeutics Piyasaya Karşı Temettü Getirisi

XRTX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (XRTX)	n/a
Pazarın Alt %25'i (CA)	1.8%
Pazarın En İyi %25'i (CA)	6.2%
Sektör Ortalaması (Pharmaceuticals)	2.4%
Analist tahmini (XRTX) (3 yıla kadar)	n/a

Önemli Temettü: XRTX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, XRTX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: XRTX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: XRTX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

XORTX Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

New major risk - Shareholder dilution

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $1.499994 million.

XORTX Therapeutics Inc. Initiates Precision Medicine Program

XORTX Therapeutics Inc. announced delayed 20-F filing

XORTX Therapeutics Inc. Appoints Abigail Jenkins to the Board of Directors

XORTX Therapeutics Inc. Appoints Ronald Perrone as Clinical Advisory Board

XORTX Therapeutics Inc. announced a financing transaction

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Board Changes

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million.

XORTX Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $3.701931 million.

New major risk - Revenue and earnings growth

XORTX Therapeutics Inc. Announces Presentation of New Research Findings At the American Society of Nephrology Meeting

XORTX Therapeutics to Consider A Consolidation of the Company’s Issued and Outstanding Shares in Order for the Company to Regain Compliance with the Continued Listing Requirements for the Nasdaq Capital Market

XORTX Therapeutics Provides Nasdaq Compliance Update

New major risk - Share price stability

Xortx Therapeutics Inc. Submits Orphan Drug Designation Application to the European Medicines Agency to Treat Progressive Kidney Disease

New major risk - Market cap size

New minor risk - Share price stability

XORTX Therapeutics Inc. Announces Chief Financial Officer Changes

XORTX Therapeutics Inc. Announces Departure of Jacqueline Le Saux

XORTX Therapeutics Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. Announces FDA Confirms Eligibility of XORLO™ for Accelerated Approval

XORTX Therapeutics Inc. Announces Goals for 2023

Xortx Therapeutics Inc. Announces Submission of Orphan Drug Designation Request for Xrx-008 Program to Treat Autosomal Dominant Kidney Disease

XORTX Therapeutics Inc. Announces Positive Topline Results from XRX-OXY-101 Clinical Trial

Investor sentiment improved over the past week

XORTX Therapeutics Inc Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

Investor sentiment improved over the past week

XORTX Therapeutics Inc. Announces Completion of Dosing in XRX-OXY-101 Clinical Study

XORTX Therapeutics Inc. Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

Investor sentiment deteriorated over the past week

XORTX Therapeutics Appoints Stacy Evans as Chief Business Officer

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives Further No Objection Letter from Health Canada

XORTX Therapeutics Inc. has completed a Composite Units Offering in the amount of $4.99964 million.

XORTX Therapeutics Inc. Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

Here's Why We're Watching XORTX Therapeutics' (CVE:XRTX) Cash Burn Situation

XORTX Therapeutics Inc. Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

High number of new and inexperienced directors

XORTX Therapeutics Inc. Announces Submission to European Medicines Agency

XORTX Therapeutics Inc. Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

XORTX Therapeutics Inc. Appoints Anthony Giovinazzo to the Board of Directors and as Chair of the Board

XORTX Therapeutics Inc., Annual General Meeting, Jul 20, 2022

XORTX Therapeutics Inc. Opens an IND for XRx-008 Program for Autosomal Dominant Polycystic Kidney Disease

XORTX Therapeutics Inc. Initiates Dosing of Human Subjects in the Xrx-Oxy-101 Clinical Trial

XORTX Therapeutics Inc. announced delayed 20-F filing

High number of new and inexperienced directors

XORTX Therapeutics Inc. Receives No Objection Letter from Health Canada

XORTX Therapeutics Inc. Announces Grant of US Patent

Xortx Therapeutics Inc. Announces Filing of an Investigational New Drug Application with the Unites States Food and Drug Administration

XORTX Therapeutics (CVE:XRTX) Is In A Strong Position To Grow Its Business

XORTX Therapeutics Inc. Provides Corporate Update for 2022

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

We're Interested To See How XORTX Therapeutics (CVE:XRTX) Uses Its Cash Hoard To Grow

XORTX Therapeutics Inc. Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

Companies Like XORTX Therapeutics (CSE:XRX) Can Afford To Invest In Growth

XORTX Therapeutics Inc., Annual General Meeting, Apr 29, 2021

XORTX Therapeutics Inc. Announces the Filing of A New Provisional Patent Application Entitled "Compositions and Methods for Enhancing Anti-Viral Therapies"

Independent Director exercised options to buy CA$91k worth of stock.

XORTX Therapeutics Inc. announced that it has received CAD 6.121572 million in funding

XORTX Therapeutics Inc. announced that it expects to receive CAD 3 million in funding

New 90-day high: CA$0.22

XORTX Announces Grant of European Patent

XORTX Therapeutics Inc. Announces Topline Results from Mount Sinai’s COVID-19 Clinical Study

XORTX Therapeutics Inc. Receives Positive Feedback from FDA on COVID-19 Related Acute Kidney Injury

New 90-day high - CA$0.27

New 90-day high - CA$0.21

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin